| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910793554503321 |
|
|
Titolo |
Textbook of clinical trials in oncology : a statistical perspective / / edited by Susan Halabi, Stefan Michiels |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Boca Raton, Florida : , : CRC Press, , [2019] |
|
|
|
|
|
|
|
ISBN |
|
1-351-62097-5 |
1-351-62096-7 |
1-315-11208-6 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (645 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cancer - Research - Statistical methods |
Clinical trials - Statistical methods |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
"A Chapman & Hall Book"--Title page. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Sommario/riassunto |
|
There is an increasing need for educational resources for statisticians and investigators. Reflecting this, the goal of this book is to provide readers with a sound foundation in the statistical design, conduct, and analysis of clinical trials. Furthermore, it is intended as a guide for statisticians and investigators with minimal clinical trial experience who are interested in pursuing a career in this area. The advancement in genetic and molecular technologies have revolutionized drug development. In recent years, clinical trials have become increasingly sophisticated as they incorporate genomic studies, and efficient designs (such as basket and umbrella trials) have permeated the field. This book offers the requisite background and expert guidance for the innovative statistical design and analysis of clinical trials in oncology. Key Features: Cutting-edge topics with appropriate technical background Built around case studies which give the work a "hands-on" approach Real examples of flaws in previously reported clinical trials and how to avoid them Access to statistical code on the book's website Chapters written by internationally recognized statisticians from academia and pharmaceutical companies Carefully edited to ensure consistency in style, level, and approach Topics covered include |
|
|
|
|
|
|
|
|
|
|
innovating phase I and II designs, trials in immune-oncology and rare diseases, among many others |
|
|
|
|
|
| |